George J. Murphy, PhD

George Murphy
617.358.0846
670 Albany St., Suite 208

Biography

I have developed an approach to science that utilizes multiple stem cell-based platforms to answer basic biological questions and combat human disease. My current research portfolio is a direct reflection of my evolution as a scientist in which my early studies of hematopoietic development led to the generation of useful tools and reagents as well as methodologies and insights that synergized into a potent platform in the emerging and rapidly expanding field of pluripotent stem cell biology. My group is composed of dynamic and passionate young researchers and together we have impacted the following areas of investigation:

1.) Developmental hematopoiesis
2.) The generation, culture, and directed differentiation of pluripotent stem cells
3.) Pluripotent stem cell-based modeling of hematopoiesis: a Platform for Production of Transfusable Human Blood Cells
4.) Pluripotent Stem Cell Modeling of Human Disease: The ‘Clinical Trial in a Test Tube’: Sickle Cell Anemia; Amyloidosis

Other Positions

  • Associate Professor, Hematology & Medical Oncology, Medicine, Boston University School of Medicine
  • Member, Pulmonary Center, Boston University
  • Co-Director, Center for Regenerative Medicine, Boston University
  • Member, Center of Excellence in Sickle Cell Disease, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
  • Member, Genome Science Institute, Boston University

Education

  • University of Oxford, PhD
  • Trinity College, BS

Publications

  • Published on 5/6/2020

    Kanchan K, Iyer K, Yanek LR, Carcamo-Orive I, Taub MA, Malley C, Baldwin K, Becker LC, Broeckel U, Cheng L, Cowan C, D'Antonio M, Frazer KA, Quertermous T, Mostoslavsky G, Murphy G, Rabinovitch M, Rader DJ, Steinberg MH, Topol E, Yang W, Knowles JW, Jaquish CE, Ruczinski I, Mathias RA. Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. Stem Cell Res. 2020 May 06; 46:101803. PMID: 32442913.

    Read at: PubMed
  • Published on 10/31/2019

    Steinberg MH, Kumar S, Murphy GJ, Vanuytsel K. Sickle cell disease in the era of precision medicine: looking to the future. Expert Review of Precision Medicine and Drug Development Personalized medicine in drug development and clinical practice. 2019; (6):357-367.

    Read at: Custom
  • Published on 4/16/2019

    Le CQ, Myers G, Habara A, Jearawiriyapaisarn N, Murphy GJ, Chui DHK, Steinberg MH, Engel JD, Cui S. Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood. 2019 05 30; 133(22):2455-2459. PMID: 30992270.

    Read at: PubMed
  • Published on 1/1/2019

    Vanuytsel K, Steinberg MH, Murphy GJ. In: Haruhisa Inoue, Yukio Nakamura (Eds.), Medical Applications of iPS Cells. https://doi.org/10.1007/978-981-13-3672-0. Recapitulating Hematopoietic Development in a Dish. Springer Nature Singapore Pte Ltd. 2019. 2019; 45-71.

    Read at: Custom
  • Published on 9/11/2018

    Seo H, Chen SJ, Hashimoto K, Endo H, Nishi Y, Ohta A, Yamamoto T, Hotta A, Sawaguchi A, Hayashi H, Koseki N, Murphy GJ, Fukuda K, Sugimoto N, Eto K. A ß1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Adv. 2018 09 11; 2(17):2262-2272. PMID: 30206099.

    Read at: PubMed
  • Published on 8/14/2018

    Vanuytsel K, Matte T, Leung A, Naing ZH, Morrison T, Chui DHK, Steinberg MH, Murphy GJ. Induced pluripotent stem cell-based mapping of ß-globin expression throughout human erythropoietic development. Blood Adv. 2018 08 14; 2(15):1998-2011. PMID: 30108108.

    Read at: PubMed
  • Published on 8/7/2018

    Ward C, Volpe G, Cauchy P, Ptasinska A, Almaghrabi R, Blakemore D, Nafria M, Kestner D, Frampton J, Murphy G, Buganim Y, Kaji K, García P. Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming. Cell Rep. 2018 08 07; 24(6):1496-1511.e8. PMID: 30089261.

    Read at: PubMed
  • Published on 7/21/2018

    Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155. PMID: 30032658.

    Read at: PubMed
  • Published on 4/1/2018

    Leung A, Zulick E, Skvir N, Vanuytsel K, Morrison TA, Naing ZH, Wang Z, Dai Y, Chui DHK, Steinberg MH, Sherr DH, Murphy GJ. Notch and Aryl Hydrocarbon Receptor Signaling Impact Definitive Hematopoiesis from Human Pluripotent Stem Cells. Stem Cells. 2018 07; 36(7):1004-1019. PMID: 29569827.

    Read at: PubMed
  • Published on 11/29/2017

    Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9. PMID: 29227829.

    Read at: PubMed

View 27 more publications: View full profile at BUMC

View all profiles